THE INFLUENCE OF GUT MICROBIOTA ON THE HUMAN IMMUNE SYSTEM

Muhammadiyev Ismail Sulaymonovich
Samarqand davlat tibbiyot universiteti, Pediatriya fakultetining 4-bosqich talabasi
+998910337667 / muxammadievismail767@gmail.com
Muhammadiyev Xamid Anvarovich
Samarqand davlat tibbiyot universiteti, Davolash fakultetining 2-bosqich talabasi
+998910327667 / ismail.muxammadiev@icloud.com
Aslamova Kamila O'ktamjonovna
Samarqand davlat tibbiyot universiteti, Davolash fakultetining 2-bosqich talabasi
+998973976708 / aslanova1977@icloud.com
Samarova Maftuna Kambarovna
Samarqand davlat tibbiyot universiteti, Davolash fakultetining 2-bosqich talabasi
+998906005070 / skmaftuna@icloud.com

Abstract: *The human gut microbiota — comprising approximately 38 trillion microorganisms — exerts profound influence on host immune system development, education, and homeostasis. This review synthesizes current mechanistic and clinical evidence regarding the gut-immune axis, focusing on short-chain fatty acid (SCFA)-mediated regulatory T cell induction, pattern recognition receptor (PRR) signaling, and the role of microbial dysbiosis in immune-mediated diseases including inflammatory bowel disease (IBD), allergic disorders, and autoimmune conditions. Data from germ-free animal models, human cohort studies, and intervention trials demonstrate that targeted microbiome modulation — through probiotics, prebiotics, dietary interventions, and fecal microbiota transplantation (FMT) — offers significant therapeutic potential. Future directions include precision microbiome medicine integrating multiomics and artificial intelligence to individualize immune-targeted therapies.*

Keywords: *gut microbiota, microbiome, immune system, dysbiosis, gut-immune axis, short-chain fatty acids, regulatory T cells, fecal microbiota transplantation, inflammatory bowel disease, probiotics.*

1. Introduction: The human gut microbiota — comprising approximately 38 trillion microorganisms representing more than 1,000 bacterial species, alongside archaea, fungi, viruses, and protozoa — constitutes one of the most complex and dynamic ecosystems in nature. Advances in high-throughput sequencing technologies, particularly 16S rRNA gene sequencing and shotgun metagenomics, have enabled unprecedented characterization of this microbial community, revealing its profound influence on host physiology, metabolism, and immune function (Sender et al., 2016).

The gut-immune axis represents a bidirectional communication network through which the microbiota profoundly shapes the development, education, and function of the host immune system. Approximately 70–80% of the body's immune cells reside in the

gastrointestinal tract's mucosa-associated lymphoid tissue (MALT), including Peyer's patches, mesenteric lymph nodes, and isolated lymphoid follicles. This anatomical proximity facilitates continuous immunological dialogue between the microbiota and the host, establishing the foundations for both protective immunity and immune tolerance (Belkaid & Hand, 2014).

Alterations in gut microbial community composition — collectively termed dysbiosis — have been associated with an expanding spectrum of immune-mediated pathologies, including inflammatory bowel disease (IBD), allergic disorders, autoimmune diseases, and metabolic conditions. This review synthesizes current evidence regarding molecular mechanisms through which gut microbiota modulate immune function, consequences of dysbiosis, and therapeutic strategies targeting the microbiome to restore immune homeostasis.

2. Mainbody:

2.1 Mechanisms of Gut-Immune Interaction : Short-chain fatty acids (SCFAs) — particularly butyrate, propionate, and acetate — produced by microbial fermentation of dietary fiber represent critical immunomodulatory mediators. Butyrate serves as the primary energy substrate for colonocytes and potently inhibits histone deacetylases (HDACs), promoting the differentiation of regulatory T cells (Tregs) in the colonic lamina propria through induction of the transcription factor FoxP3 (Furusawa et al., 2013). This mechanism is fundamental to the establishment of peripheral immune tolerance and prevention of excessive inflammatory responses.

Pattern recognition receptors (PRRs), including Toll-like receptors (TLRs) and NOD-like receptors (NLRs), recognize microbiota-derived pathogen-associated molecular patterns (PAMPs) including lipopolysaccharide (LPS), peptidoglycan, and flagellin. This constant PRR stimulation is essential for maintaining intestinal epithelial barrier integrity, driving immunoglobulin A (IgA) production, and calibrating innate immune tone (Honda & Littman, 2016).

2.2 Microbiota and Adaptive Immunity : Germ-free animal studies have conclusively demonstrated that colonization with commensal bacteria is essential for normal thymic development, peripheral T cell homeostasis, and germinal center reactions. The cytokine milieu established by microbial signals directs CD4+ T helper cell differentiation — with specific microorganisms promoting Th1, Th2, Th17, or Treg polarization depending on the inflammatory context (Ivanov et al., 2017).

Segmented filamentous bacteria (SFB) potently induce Th17 cell differentiation in the intestinal lamina propria, providing critical protection against extracellular pathogens. Conversely, Clostridia species promote Treg differentiation and IL-10 production, establishing anti-inflammatory tone. The balance between Th17 and Treg populations — substantially regulated by microbial community composition — is a critical determinant of susceptibility to both infectious and autoimmune diseases.

2.3 Dysbiosis and Immune-Mediated Disease: In inflammatory bowel disease (IBD), both Crohn's disease and ulcerative colitis are characterized by reduced microbial diversity, decreased Firmicutes (particularly Faecalibacterium prausnitzii), and expansion

of Proteobacteria. These compositional shifts reduce butyrate production, compromise epithelial barrier integrity, and potentiate NF-kB-mediated inflammatory cascades (Ni et al., 2017).

The 'old friends' hypothesis proposes that reduced microbial exposure in industrialized societies impairs immunological education, contributing to rising prevalence of allergic and autoimmune conditions. Epidemiological data strongly support this framework: children raised in farm environments with high microbial exposure have significantly lower rates of asthma, atopy, and type 1 diabetes compared with urban peers.

2.4 Therapeutic Modulation of the Microbiome: Probiotic interventions using well-characterized strains — including Lactobacillus rhamnosus GG, Bifidobacterium longum, and Saccharomyces boulardii — have demonstrated evidence-based efficacy in antibiotic-associated diarrhea, acute infectious diarrhea, and necrotizing enterocolitis prophylaxis in premature neonates (Hill et al., 2014). Prebiotic supplementation with inulin, fructooligosaccharides (FOS), and galactooligosaccharides (GOS) selectively promotes beneficial taxa and SCFA production.

Fecal microbiota transplantation (FMT) has achieved the highest level of evidence (Level 1A) for recurrent Clostridioides difficile infection, with cure rates exceeding 90% compared with 30–50% for antibiotics alone (van Nood et al., 2013). The emerging field of live biotherapeutic products (LBPs) — precisely defined microbial consortia — represents the next generation of microbiome-based immunotherapeutics, offering greater safety and reproducibility than conventional FMT.

3. Conclusion: The gut microbiota emerges as a pivotal modulator of human immune system development, function, and homeostasis. Through diverse molecular mechanisms encompassing SCFA production, PRR engagement, cytokine modulation, and lymphocyte differentiation, commensal microorganisms continuously shape immune responses at local and systemic levels. Dysbiosis contributes significantly to the pathogenesis of numerous immune-mediated disorders from IBD and allergic conditions to autoimmune and metabolic diseases.

Future directions include precision microbiome medicine — tailoring interventions to individual microbiome profiles, host immune genotypes, and disease phenotypes — enabled by integration of multiomics data with artificial intelligence-based analytics. Elucidating causal rather than merely associative relationships between specific microbial communities and immune outcomes remains the central challenge for translating microbiome science into clinical practice.

REFERENCES

1. Belkaid, Y., & Hand, T. W. (2014). Role of the microbiota in immunity and inflammation. Cell, 157(1), 121–141.

2. Sender, R., Fuchs, S., & Milo, R. (2016). Revised estimates for the number of human and bacteria cells in the body. Cell, 164(3), 337–340.

3. Furusawa, Y., et al. (2013). Commensal microbe-derived butyrate induces colonic regulatory T cells. Nature, 504(7480), 446–450.

4. Honda, K., & Littman, D. R. (2016). The microbiota in adaptive immune homeostasis and disease. Nature, 535(7610), 75–84.

5. Ivanov, I. I., et al. (2017). Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell, 139(3), 485–498.

6. Ni, J., et al. (2017). Gut microbiota and IBD: causation or correlation? Nature Reviews Gastroenterology & Hepatology, 14(10), 573–584.

7. Hill, C., et al. (2014). The ISA consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews Gastroenterology & Hepatology, 11(8), 506–514.

8. van Nood, E., et al. (2013). Duodenal infusion of donor feces for recurrent Clostridium difficile. NEJM, 368(5), 407–415.

9. Vatanen, T., et al. (2018). The human gut microbiome in early-onset type 1 diabetes. Nature, 562(7728), 589–594.

10. Sonnenburg, J. L., & Backhed, F. (2016). Diet-microbiota interactions as moderators of human metabolism. Nature, 535(7610), 56–64.

11. Zmora, N., Suez, J., & Elinav, E. (2019). You are what you eat: diet, health and the gut microbiota. Nature Reviews Gastroenterology & Hepatology, 16(1), 35–56.

12. Shreiner, A. B., Kao, J. Y., & Young, V. B. (2015). The gut microbiome in health and in disease. Current Opinion in Gastroenterology, 31(1), 69–75.